Lexicon Pharmaceuticals (LXRX) Proxy Filing summary

Voting matters and shareholder proposals

• Election of three directors: Samuel L. Barker, Ph.D., Christopher J. Sobecki, and Judith L. Swain, M.D. is up for shareholder vote, with board recommendation to vote in favor.

• Ratification and approval of the Seventh Amended and Restated Certificate of Incorporation is proposed, with board support.

• Approval of the 2026 Equity Incentive Plan and the 2026 Non-Employee Directors' Equity Incentive Plan is recommended by the board.

• Advisory vote on executive compensation for named executive officers is included, with board recommendation to approve.

• Ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, is proposed.

Board of directors and corporate governance

• Three director nominees are presented for election at the annual meeting.

Executive compensation and say-on-pay

• Advisory vote on executive compensation for named executive officers is scheduled, with board recommendation to approve.